|
Our Mission:
TREVENTIS research will make a meaningful difference in the lives of patients with Alzheimer's disease (AD) by using its proprietary technologies to discover and initiate development of wholly novel and proprietary drugs that halt progression, stabilize and potentially improve the patient's cognition.
Our Disease Focus:
AD, the leading cause of dementia in the elderly, is characterized by reduction of memory and cognitive skills through loss of or impaired function of synaptic connections in the brain. Therapeutic options for patients and clinicians are very limited. Research to discover the cause and to develop therapeutic options is focused on cellular pathways and targets that, if modulated, may result in halting the progression of AD and/or improving a patient's cognition. Most therapeutic options in development address a single cause (target), generally beta amyloid (Aß). The Aß hypothesis was proposed in Science in 2002 by Hardy and Selkoe who postulated that "neurodegeneration in AD may be caused by deposition of Aß plaques in brain tissue." They concluded that Aß plaque formation is the primary pathogenic event causing neuronal death and resulting in a focus solely on Aß. The recent clinical failure of Aß-only targeted drugs (Alzhemed® and Flurizan®) underscores the need to develop drugs that modulate more than one target.
Our Technology:
At TREVENTIS, research is focused on multiple targets, including Aß and tau. The Company's discovery efforts are seeking targets common to both Aß and tau as well as single new chemical entities (NCEs) that modulate this shared target. The Company discovered and confirmed the existence of a common conformational region (CCM) on multiple amyloid proteins that is common to both Aß and tau. TREVENTIS has also developed a proprietary discovery platform: a high-resolution three-dimensional (3D) "in silico" (computer-based) model of the CCM, enabling rational design of multiple lead compounds.
Our People:
Chris Barden, PhD: Discovery and validation of the CCM platform, the TREVENTIS computerized, "in silico" model of Aß protein and de novo drug design.
Sultan Darvesh, MD, PhD: Professor of Medicine (Anatomy and Neurology) and Chemistry, Dalhousie University responsible for TREVENTIS diagnostics.
L. William McIntosh, BS, MBA: 30-year veteran of the industry in positions at Merck, Medco, Boehringer Mannheim, Zynaxis, GlaxoSmithKline, Nexell, FASgen, Q-RNA, Neuro-Hitech.
Mark A. Reed, BSc, DPhil: Senior Research Scientist Schering-Plough; Medicinal and Process Chemist ICOS.
Donald Weaver, MD, PhD: Canada Research Chair Neuroscience; Professor of Medicine (Neurology), Biomedical Engineering and Chemistry at Dalhousie University in Nova Scotia.
William Wong, PhD: Senior management experience at Becton-Dickinson, DuPont, Zynaxis, Intracel, Nexell, Lynx Therapeutics, Q-RNA, Neuro-Hitech.
More Information: Contact L. William (Bill) McIntosh at wmcintosh@TREVENTIS.com |